Here, we used data obtained from the ASTRIO study to evaluate the relationship between FGF23 and α-klotho during treatment with an iron-based phosphate binder (FC), compared with non-iron-based phosphate binders, in patients with CKD who were undergoing HD. Here, FGF23 is linked to chronic kidney disease.